Amphastar Pharmaceuticals, Inc.
NASDAQ:AMPHDrug Manufacturers - Specialty & Generic
-$0.31 today
- Market cap
- $1.27B
- Beta
- 0.90
- P/E (TTM)
- 10.9
- EPS (TTM)
- $1.75
Volume 0.53M
Average 0.59M
AMPH EBITDA Margin
EBITDA as a percentage of revenue.
Amphastar Pharmaceuticals, Inc.NASDAQ: AMPH
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to 19.3%
EBITDA Margin was 19.3% in Q1 FY2026, down 11.4 pp from a year earlier. On a trailing-twelve-month basis it was 26.6%, down 9.0 pp year over year. Over 3 fiscal years it widened by 0.2 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 4 analysts of 35.1% for the fiscal year ending Dec 2026, up from 29.5% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 19.3%-10.4 pp QoQ
- Last fiscal yearDec 2025
- 29.5%-8.4 pp YoY
- LTMMar 2026
- 26.6%-9.0 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -11.4 pp | -3.9 pp | +7.5 pp |
| 1 year | -8.4 pp | +5.6 pp | +14.0 pp |
| 3 years | +0.2 pp | +6.6 pp | +6.4 pp |
| 5 years | +2.0 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 29.5%
- Year-over-year change
- -8.4pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 29.5% | -8.4pp |
| FY2024 | 2024-12-31 | 37.9% | +0.6pp |
| FY2023 | 2023-12-31 | 37.3% | +8.0pp |
| FY2022 | 2022-12-31 | 29.3% | +3.8pp |
| FY2021 | 2021-12-31 | 25.5% | — |
EBITDA Margin vs competitors
How AMPH compares with its peers on the latest reported figures
- AMPH's LTM Mar 2026 EBITDA Margin of 26.6% is the 2nd highest of the 8 companies compared; the peer median is 18.4%.
- Its year-over-year change of -9.0 pp is the 6th highest of 8, against a peer median of +0.5 pp.
- Over three fiscal years its change of +0.2 pp compares with a peer median of +0.1 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 76.6% | +26.5 pp | +14.0 pp | |
| LTM Mar 2026 | 26.6% | -9.0 pp | +0.2 pp | |
| LTM Jun 2026 | 20.9% | +0.5 pp | +0.1 pp | |
| LTM Jun 2026 | 18.9% | -14.3 pp | -4.5 pp | |
| LTM Jun 2026 | 18.4% | +21.9 pp | -42.3 pp | |
| LTM Sep 2026 | 16.3% | -12.5 pp | -6.7 pp | |
| LTM Jun 2026 | 15.0% | -2.9 pp | +24.4 pp | |
| LTM Mar 2026 | 6.3% | +9.1 pp | +39.4 pp | |
| Peer median (excluding AMPH) | 18.4% | +0.5 pp | +0.1 pp | |
Competitors are the stored peer set for AMPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 437.77M | 498.99M | 644.4M | 731.97M | 719.89M |
| Cost of Revenue | 238.03M | 250.13M | 293.27M | 358.11M | 363.83M |
| Gross Profit | 199.74M | 248.86M | 351.12M | 373.86M | 356.06M |
| Gross Margin | 45.6% | 49.9% | 54.5% | 51.1% | 49.5% |
| Research & Development | 60.93M | 74.77M | 73.74M | 73.91M | 85.84M |
| Selling, General & Admin | 68.92M | 66.59M | 80.39M | 94.52M | 129.81M |
| Operating Expenses | 129.85M | 141.36M | 154.13M | 168.44M | 215.65M |
| Depreciation & Amortization | 26.53M | 28.28M | 41.78M | 57.21M | 63.2M |
| EBITDA | 111.56M | 146.16M | 240.29M | 277.31M | 212.31M |
| EBITDA Margin | 25.5% | 29.3% | 37.3% | 37.9% | 29.5% |
| Operating Income | 69.89M | 107.5M | 196.99M | 205.42M | 140.4M |
| Operating Margin | 16.0% | 21.5% | 30.6% | 28.1% | 19.5% |
| Interest Income | 601K | 1.32M | 5.46M | 10.61M | 8.68M |
| Interest Expense | 885K | 1.85M | 27.16M | 30.34M | 25.48M |
| Other Income / Expenses | 14.04M | 7.37M | (27.61M) | (16.23M) | (16.78M) |
| Income Before Tax | 83.93M | 114.86M | 169.38M | 189.19M | 123.62M |
| Pre-Tax Margin | 19.2% | 23.0% | 26.3% | 25.8% | 17.2% |
| Income Tax Expense | 20.63M | 23.48M | 31.83M | 29.67M | 25.53M |
| Net Income | 62.12M | 91.39M | 137.55M | 159.52M | 98.09M |
| Net Margin | 14.2% | 18.3% | 21.3% | 21.8% | 13.6% |
| EPS (Basic) | 1.30 | 1.88 | 2.85 | 3.29 | 2.10 |
| EPS (Diluted) | 1.25 | 1.74 | 2.60 | 3.06 | 2.03 |
| Weighted Avg Shares | 47.78M | 48.55M | 48.27M | 48.43M | 46.74M |
| Weighted Avg Shares (Diluted) | 49.78M | 52.43M | 53M | 52.06M | 48.22M |
Amphastar Pharmaceuticals, Inc.
NASDAQ:AMPH
Intrinsic Alpha fair value
Locked
Current Price
$29.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.